Fox Chase Cancer Center, part of Temple University Health System, is an NCI-designated comprehensive cancer center and has maintained this prestigious status for 50 years. Founded in 1904 as one of the nation’s first cancer hospitals, Fox Chase has a distinguished legacy of groundbreaking discoveries, including the Philadelphia chromosome, which revolutionized cancer genetics and led to the development of Gleevec. The center continues to lead through more than 500 active research projects supported by $80 million in annual funding and a robust portfolio of 230 clinical trials, nearly half of which are investigator-initiated. Fox Chase was the first cancer hospital in Pennsylvania to achieve Magnet designation for nursing excellence, earning six consecutive renewals. A founding member of the National Comprehensive Cancer Network, Fox Chase pioneers advances in adaptive radiation therapy, precision breast-conserving surgery and novel leukemia treatments.
